Rajesh Laddha

CFO, Piramal Group

Khushru Jijina

MD, Piramal Fund Management



Managing Director, Piramal Fund Management

Mr. Khushru Jijina is the Managing Director of Piramal Fund Management Private Limited (PFM), the largest real estate fund and investment management platform in India. As Managing Director, he oversees the entire spectrum of activities ranging from origination, investments, asset management, exits and new fund raising performed by an 80+ member management team under his supervision. Apart from being a key man for PFM, Mr. Jijina also serves as Group Treasurer and leads the Family Office for all proprietary investments.

Mr. Jijina is a Chartered Accountant by profession with an illustrious career spanning over two decades in the field of real estate, corporate finance and treasury management and has been with the Piramal Group for more than 15 years. Prior to PFM, Mr. Jijina was spearheading the Group's foray into real estate development as the Managing Director of Piramal Realty. Previously, he was an Executive Director in Piramal Sunteck Realty, where he was responsible for a portfolio of projects spanning Mumbai, Navi Mumbai, Nagpur, Jaipur and Oman and oversaw all aspects of their execution. He started his career with Rallis, where he held several important positions in corporate finance for over 12 years.

The Piramal Fund Management platform, under his leadership, is organised around an integrated approach to real estate funding; and is capable of catering to the entire capital stack i.e. early state private equity, structured/mezzanine equity, structured debt, senior secured debt, construction finance as well as bulk buying of individual residential units. PFM currently manages/advises an AUM of $1.8bn, in addition to a proprietary debt book with gross disbursements worth of $1.6bn. In 2014, PFM also formalised a $0.5bn strategic joint venture (JV) with Canadian Pension Plan Investment Board (CPPIB) for high yield residential debt funding, the largest FDI investment into India since 2005.

The platform has been widely recognised for its several successes including being awarded the Firm of the Year – India as well as the Debt Fund Manager of the Year – Asia, by the PEI Global Private Equity Real Estate (PERE) awards; and the 'Best Overall Investment Manager – India' by Euromoney in 2015. In addition, PFM was also voted as the 'Best Domestic Fund House' by CNBC Awaaz in 2014.

Peter DeYoung

CEO, Critical Care



Chief Executive Officer, Critical Care

Mr. Peter DeYoung is the CEO of Piramal Critical Care. He is a member of the Piramal Pharma Operating Board and also a member of the Board of Piramal Imaging SA.

Prior to joining Piramal, he worked in a range of investing and consulting roles in healthcare in the US, Europe and India. He joined McKinsey & Company in New York after graduating from Princeton, where he worked on a number of projects for pharmaceutical and medical device companies. He was then seconded by McKinsey to the World Economic Forum in Geneva, Switzerland as a Project Manager for the Global Health Initiative, where he implemented an HIV/AIDS, TB and malaria advocacy strategy focused on boosting private sector programmes in South East Asia and Africa. He then returned to McKinsey as an Engagement Manager in New York and later in Mumbai, where he focused on the pharmaceutical and healthcare practice. He helped clients address a range of strategic, organisational, and operational challenges. He then went on to join the Blackstone's Private Equity Group in Mumbai. He was on the deal team for several significant transactions across a variety of industry sectors in India.

He completed his Bachelors of Science in Engineering from Princeton University, New Jersey, USA (summa cum laude, phi beta kappa, tau beta pi) and his Masters of Business Administration at Stanford University (Arjay Miller Scholar), California, USA.

Vivek Sharma

CEO, Pharma Solutions



Chief Executive Officer, Pharma Solutions

Mr. Vivek Sharma currently serves as the CEO of Piramal Pharma Solutions (PPS), a global leader in providing Contract Research, Development and Manufacturing services towards the life sciences industry. PPS offers integrated solutions from discovery through development and commercialisation, with research and manufacturing facilities in North America, Europe, and Asia. Under his leadership, PPS has been voted 'global top 10% CMO' for 2014 and 2015. He started his stint in the Piramal Group by heading the Piramal Critical Care (PCC) business and was instrumental in improving profitability and establishing it as the third largest and the fastest growing Inhalation Anesthetics company globally. Prior to Piramal, Mr. Sharma was Managing Director at THL Partners, a Boston based global private equity fund, and has held senior leadership positions in Finance and Operations at AMD and Motorola. He was recently awarded the 'CEO Of The Year' at CPhi 2015 and has been listed among 'the top 100 finance professionals in the United States'. He is based out of Boston and is a Chartered Accountant from India. Besides, he is a qualified CPA, and holds a Masters in International Business from Thunderbird School of Management.

Jon Sandler




Chief Executive Officer, Decision Resources Group

Mr. Jon Sandler is the CEO of Decision Resources Group (DRG), Piramal's Health Care Information subsidiary. DRG offers high-value data, analytics and insights products and services to the global healthcare industry. Mr. Sandler, who joined Piramal in 2011, also serves as Managing Director of IndUS Growth Partners, Piramal's North American strategic investment affiliate. Prior to joining Piramal, he spent 17 years at the Kessler Group, a financial services boutique, where he served as Vice Chairman, Group CFO, founding CEO of Kessler International and founding CEO of Kessler Capital. In these roles, Mr. Sandler was responsible for driving the company's growth, diversification, global expansion, operating effectiveness and profit expansion. He began his career as an investment banker at Bankers Trust Company in New York and then as a strategy consultant with the MAC Group in Cambridge. He received a BA and MBA from Harvard University. He is on the Board of Piramal Imaging and Bluebird Aerosystems. Besides, he is a Trustee of Combined Jewish Philanthropies.

Kedar Rajadnye

COO, Consumer Products



Chief Operating Officer, Consumer Products

Mr. Kedar Rajadnye is the COO of the Consumer Products business of Piramal Enterprises, one of the fastest growing self-care businesses in India. He is also responsible for the IT function of the Piramal Group.

He joined the Piramal Group in 2004 to head a portfolio of domestic pharmaceutical business. Since 2008, he has been responsible for the Consumer Products division, which is consistently growing faster than the market. Over the years in the Indian OTC market, it has moved up from 40th rank in 2007 to the current 7th rank.

Under his stewardship, the business has built one of the strongest Chemist distribution capabilities in India. He has played an influential role in building strong OTC brands such as Lacto Calamine, Saridon, Ipill, Tetmosol and Caladryl. Most of these brands are ranked either no.1 or no.2 in their respective categories. He was instrumental in acquisitions of Little's, Naturolax, Lactobacilus and other brands last year.

Prior to joining the Group, Mr. Rajadnye has worked at Hindustan Unilever for eight years in the sales and marketing division. He is an alumnus of Jamnalal Bajaj Institute of Management Studies and has also completed the Executive Development programme from the Harvard Business School.

Jayesh Desai

Co-Head, Structured Investments Group



Co-Head, Structured Investments Group

Mr. Jayesh Desai is the Managing Partner of Structured Investments Group at Piramal Enterprises Limited, Mumbai, India.

Mr. Desai joined the Company in April 2012, heading the Structured Investments Group which provides structured mezzanine funding to corporates in various sectors, including infrastructure.

Mr. Desai is a Chartered Accountant with professional experience of over 25 years in the field of corporate finance, financial services and infrastructure advisory. Over the years, he has been instrumental in setting-up and running businesses in various capacities in Ernst & Young (E&Y), Coca-Cola and Piramal. He has spent 15 years with E&Y (as Director for Infrastructure and National Director for Transaction Advisory Service, Head of Operations) and six years with Coca-Cola (Vice-President, Business Development).

Mr. Desai was instrumental in conceptualising and implementing the Structured Investments Group at Piramal Enterprises Limited. He was instrumental in concluding a strategic alliance with the world's second-largest pension fund viz., APG Asset Management. The alliance has jointly committed to investing US$ 1 billion in Indian Infrastructure.

Over the last four years he has concluded investments in excess of US$500 million across diverse sectors such as infrastructure, renewables and cement.

Shantanu Nalavadi

Co-Head, Structured Investments Group



Co-Head, Structured Investments Group

Mr. Shantanu Nalavadi co-heads the Structured Investments Group (SIG) at Piramal Enterprises. He joined the SIG division in April 2015.

Mr. Nalavadi carries with him over two decades of experience in financial services, banking and corporate finance. Prior to joining the Group, he was a Partner with New Silk Route Advisors Pvt. Ltd. (NSR), a private equity fund with over $ 850 million in assets under management. Mr. Nalavadi brings with him the experience of investing, creating value and monetising investments across several sectors, including financial services, consumer products, media, logistics and manufacturing. In creating value for his portfolio companies, he actively participated in partnering with managements for operational improvements, competitive marketing positioning and sustainable expansion. Prior to working at NSR, he worked with ANZ Grindlays Bank, Star TV and Walt Disney with P/L and business development responsibilities.

Mr. Nalavadi articled with Arthur Andersen, India, before qualifying as a Chartered Accountant in 1993.

Dr. Dinkelborg Ludger

MD, Imaging



Managing Director, Imaging

Dr. Ludger Dinkelborg leads the Imaging Division of Piramal Enterprises. This division was created through the acquisition of worldwide rights for the Molecular Imaging Research and Development Portfolio of Bayer Pharma AG.

Before co-founding Piramal Imaging, Dr. Ludger served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer HealthCare. He has over 20 years of R&D experience in the pharmaceutical industry.

He received his PhD in Biology from Heinrich-Heine-University, Düsseldorf, and stayed as guest researcher at the Max-Planck-Institute for Molecular Physiology in Dortmund. He became a fellow of the Konrad- Adenauer-Foundation, attended the Cranfield Schering University course for managers and also attended the Executive Programme at Stanford School of Business, CA.